Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5632658 | 0.88 | KDM4E (0.44) | BRD4ALDH1A1TACR1KMT2AKDM4E | |
| SCHEMBL4419725 | 0.83 | BRD4 (0.67) | BRD4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4637805 | 0.78 | GAA (0.52) | ALDH1A1GAATACR1KDM4EHTT | |
| SCHEMBL4638473 | 0.73 | ALDH1A1 (0.65) | ALDH1A1GAASMN1; SMN2POLB | |
| Trifluoroacetic Acid SCHEMBL4737901 | 0.72 | BRD4 (0.51) | BRD4GAAPOLB | |
| SCHEMBL4638859 | 0.71 | SMN1; SMN2 (0.43) | ALDH1A1GAATACR1KMT2AKDM4E | |
| SCHEMBL4639437 | 0.71 | TACR1 (0.43) | ALDH1A1GAATACR1 | |
| SCHEMBL20603196 | 0.70 | L3MBTL1 (0.57) | ALDH1A1GAAKMT2AKDM4EHTT | |
| SCHEMBL30379055 | 0.70 | L3MBTL1 (0.57) | ALDH1A1GAAKMT2AKDM4EHTT | |
| SCHEMBL4706776 | 0.70 | ALDH1A1 (0.54) | ALDH1A1GAASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | BRD4 4297/4885ALDH1A1 1988/4885GAA 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.